StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) income statement

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$34.42−1.49 (-4.15%)

Close on Nov 18, 2026Market cap $1.18BP/E –Yield –

Nektar Therapeutics income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
100.0%
Operating margin
-253.7%
Net margin
-297.1%
Return on equity, FY2025
-217.9%

Financial strength

Current ratio
10.42
Debt to equity
–
Debt to assets
–
Cash to current liabilities
55.3%

Valuation

P/E ratio
–
Price to sales
21.28
Price to book
1.30
Dividend yield
–

See a number that looks wrong?